Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 16

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 16
---
 Direct Offering would not otherwise result in the Investor, together with their affiliates and certain related parties, beneficially owning more than 4.99% or 9.99% of our Ordinary Shares immediately following the consummation of the July 2024 Registered Direct Offering. EachJuly 2024 Pre-Funded Warrant represents the right to purchase one Depositary Share at an exercise price of $0.0025 per share. TheJuly 2024 Pre-Funded Warrants are exercisable immediately and may be exercised at any time until theJuly 2024 Pre-Funded Warrants are exercised in full.

Additionally,
in the concurrent July 2024 Private Placement, we issued and sold to the Investors (i) Series J warrants, or the Series J Warrants, exercisable
for 213,188 Depositary Shares, and (ii) Series K warrants, or Series K Warrants, to purchase an aggregate of 213,188 Depositary Shares.
The warrants are immediately exercisable at an exercise price of $25.00 per Depositary Share, subject to adjustments for certain dilutive
equity issuances. The Series J Warrants will expire five years from the initial exercise date and the Series K Warrants will expire one
year from the initial exercise date. The Investors (together with their respective affiliates) may not exercise the warrants if the
Investor would beneficially own more than 4.99% or 9.99% (such amount to be determined at the option of the Investor upon issuance) of
the number of Ordinary Shares outstanding immediately after giving effect to such exercise. The purchase agreement, or July Purchase Agreement,
contains customary representations, warranties and covenants of the Company and each Investor, and customary indemnification provisions
for a transaction of this type. Pursuant to the terms of the July Purchase Agreement, we agreed to be subject to a lock-up period on subsequent
equity sales, which has since expired. We also agreed to not issue any securities that are subject to a price reset based on the trading
prices of our Ordinary Shares or upon a specified or contingent event in the future or enter into any agreement to issue securities at
a future determined price for a period of 180 days following the closing date of the Offerings, subject to certain exceptions. Additionally,
we agreed to reduce the exercise price of our existing Series E warrants, Series G warrants and Series H warrants held by each Investor
to $25.00 per Depositary Share.

In
connection with the